{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:50:15Z","timestamp":1776289815294,"version":"3.50.1"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Coronavirus disease 2019 (COVID-19) have brought great disaster to mankind, and there is currently no globally recognized specific drug or treatment. Severe COVID-19 may trigger a cytokine storm, manifested by increased levels of cytokines including interleukin-17 (IL-17), so a new strategy to treat COVID-19 may be to use existing IL-17 inhibitors, which have demonstrated efficacy, safety and tolerability in the treatment of psoriasis. However, the use of IL-17 inhibitors in patients with psoriasis during the COVID-19 pandemic remains controversial due to reports that IL-17 inhibitors may increase the risk of respiratory tract infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The systematic review and meta-analysis aimed to evaluate the effect of IL-17 inhibitors on the risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Databases (including Embase, PubMed, SCI-Web of Science, Scopus, CNKI, and the Cochrane Library) were searched up to August 23, 2022, for studies exploring differences in COVID-19 outcomes between psoriasis patients using IL-17 inhibitors and those using non-biologics. Two authors independently extracted data and assessed the risk of bias in a double-blind manner. The risk ratios (RRs) and 95% confidence intervals (CIs) were calculated and heterogeneities were determined by the <jats:italic>Q<\/jats:italic> test and <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> statistic. And the numbers needed to treat (NNTs) were calculated to assess the clinical value of IL-17 inhibitors in preventing SARS-CoV-2 infection and treating COVID-19.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nine observational studies involving 7,106 participants were included. The pooled effect showed no significant differences in the rates of SARS-CoV-2 infection (<jats:italic>P<\/jats:italic> = 0.94; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> = 19.5%), COVID-19 hospitalization (<jats:italic>P<\/jats:italic> = 0.64; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> = 0.0%), and COVID-19 mortality (<jats:italic>P<\/jats:italic> = 0.32; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> = 0.0%) in psoriasis patients using IL-17 inhibitors compared with using non-biologics. Subgroup analyses grouped by age and COVID-19 cases, respectively, revealed consistent results as above. Meanwhile, the pooled NNTs showed no significant differences between the two groups in the clinical value of preventing SARS-CoV-2 infection and treating COVID-19.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The use of IL-17 inhibitors in patients with psoriasis does not increase the risk of SARS-CoV-2 infection or worsen the course of COVID-19.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>, identifier CRD42022335195.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1046352","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T10:24:11Z","timestamp":1666347851000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Meitong","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saijin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangran","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoyun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaning","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"B1","unstructured":"WHO coronavirus (COVID-19) dashboard2022"},{"key":"B2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/s0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30628-0","article-title":"Covid-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111980","article-title":"Interleukin-17a (Il-17a): A silent amplifier of covid-19","volume":"142","author":"Maione","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/jir.S278335","article-title":"Inflammatory cytokine: Il-17a signaling pathway in patients present with covid-19 and current treatment strategy","volume":"13","author":"Shibabaw","year":"2020","journal-title":"J Inflammation Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14437","article-title":"Potential role of il-17 blocking agents in the treatment of severe covid-19","volume":"87","author":"Bulat","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwaa037","article-title":"Elevated plasma levels of selective cytokines in covid-19 patients reflect viral load and lung injury","volume":"7","author":"Liu","year":"2020","journal-title":"Natl Sci Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.30047","article-title":"Th17 and treg cells function in sars-Cov2 patients compared with healthy controls","volume":"236","author":"Sadeghi","year":"2020","journal-title":"J Cell Physiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1089\/vim.2020.0177","article-title":"T Helper 17 response to severe acute respiratory syndrome coronavirus 2: A type of immune response with possible therapeutic implications","volume":"34","author":"Sarmiento-Monroy","year":"2021","journal-title":"Viral Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15879","article-title":"Biologic therapies targeting the interleukin (Il)-23\/Il-17 immune axis for the treatment of moderate-to-Severe plaque psoriasis: A systematic review and meta-analysis","volume":"34","author":"Erichsen","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13687","article-title":"Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the covid-19 pandemic","volume":"33","author":"Ricardo","year":"2020","journal-title":"Dermatol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-Severe psoriasis through 5 years of treatment (Sculpture extension study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jaad.2018.03.047","article-title":"Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis","volume":"79","author":"Zachariae","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.095","article-title":"Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator\u2013controlled phase 3 amagine-2 trial","volume":"82","author":"Puig","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e14498","DOI":"10.1111\/dth.14498","article-title":"Immunosuppressive drugs for patients with psoriasis during the covid-19 pandemic era","volume":"34","author":"Sadeghinia","year":"2020","journal-title":"A Review Dermatol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.035","article-title":"The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the covid-19 pandemic","volume":"83","author":"Wan","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.031","article-title":"Should biologics for psoriasis be interrupted in the era of covid-19","volume":"82","author":"Lebwohl","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The prisma 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (Strobe): Explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PloS Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2021.01.005","article-title":"Impact of the covid-19 pandemic on children with psoriasis","volume":"148","author":"Beytout","year":"2021","journal-title":"Annales Dermatol Venereol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14516","article-title":"Does therapy with biological drugs influencecovid-19 infection? observational monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone","volume":"33","author":"Brazzelli","year":"2020","journal-title":"Dermatol Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e13475","DOI":"10.1111\/dth.13475","article-title":"Biologics increase the risk of sars- cov -2 infection and hospitalization, but not icu admission and death: Real-life data from a Large cohort during red-zone declaration","volume":"33","author":"Damiani","year":"2020","journal-title":"Dermatol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16761","article-title":"Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of covid-19","volume":"34","author":"Fougerousse","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14691","article-title":"The impact of covid-19 in patients with psoriasis: A multicenter study in Istanbul","volume":"34","author":"Kara Polat","year":"2020","journal-title":"Dermatol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1927947","article-title":"The impact of covid-19 pandemic on psoriasis patients, and their immunosuppressive treatment: A cross-sectional multicenter study from Turkey","volume":"33","author":"Kartal","year":"2021","journal-title":"J Dermatol Treat"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1905766","article-title":"Risk of covid-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors","volume":"33","author":"Kridin","year":"2021","journal-title":"J Dermatol Treat"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13961","article-title":"Covid-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in north Spain","volume":"33","author":"Queiro Silva","year":"2020","journal-title":"Dermatol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2020.8642","article-title":"Psoriasis, biological drugs and coronavirus disease 2019: Real life experience of two Italian provinces","volume":"12","author":"Vispi","year":"2020","journal-title":"Dermatol Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.09.015","article-title":"From il-15 to il-33: The never-ending list of new players in inflammation. is it time to forget the humble aspirin and move ahead","volume":"79","author":"D\u2019Acquisto","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.53","article-title":"The il-23-Il-17 axis in inflammatory arthritis","volume":"11","author":"Lubberts","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/ar1444","article-title":"Biology of recently discovered cytokines: Interleukin-17\u2013a unique inflammatory cytokine with roles in bone biology and arthritis","volume":"6","author":"Gaffen","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01782.x","article-title":"Expression, modulation and signalling of il-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis","volume":"127","author":"Kehlen","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2020.03.005","article-title":"Th17 responses in cytokine storm of covid-19: An emerging target of Jak2 inhibitor fedratinib","volume":"53","author":"Wu","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e15003","DOI":"10.1111\/dth.15003","article-title":"Tumor necrosis factor inhibitors are associated with a decreased risk of covid-19-Associated hospitalization in patients with psoriasis-a population-based cohort study","volume":"34","author":"Kridin","year":"2021","journal-title":"Dermatol Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with sars-Cov-2 pneumonia in wuhan, China: A single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20181987","article-title":"Correlations of il-17 and nf-\u03bab gene polymorphisms with susceptibility and prognosis in acute respiratory distress syndrome in a Chinese population","volume":"39","author":"Xie","year":"2019","journal-title":"Biosci Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.4covcra0820-481rrr","article-title":"Neutrophils mediate Th17 promotion in covid-19 patients","volume":"109","author":"Parackova","year":"2021","journal-title":"J Leukoc Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.85851","article-title":"Cardiac myosin-Th17 responses promote heart failure in human myocarditis","volume":"1","author":"Myers","year":"2016","journal-title":"JCI Insight"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.08.034","article-title":"Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: Findings from the biobadaderm registry","volume":"137","author":"D\u00e1vila-Seijo","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00605-8","article-title":"Coronavirus disease 2019 (Covid-19)-Associated hospitalization and mortality in patients with psoriasis: A population-based study","volume":"22","author":"Kridin","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.29639","article-title":"Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and covid-19","volume":"4","author":"Izadi","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.09.009","article-title":"Clinical outcomes of covid-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study","volume":"84","author":"Yousaf","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108324","article-title":"Methotrexate as a safe immunosuppressive agent during the covid-19 pandemic","volume":"101","author":"IGanjei","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116935","article-title":"Part ii. high-dose methotrexate with leucovorin rescue for severe covid-19: An immune stabilization strategy for sars-Cov-2 induced 'Panic' attack","volume":"415","author":"Frohman","year":"2020","journal-title":"J Neurol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116942","article-title":"Silencing of immune activation with methotrexate in patients with covid-19","volume":"415","author":"Safavi","year":"2020","journal-title":"J Neurol Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002331","article-title":"The sars-Coronavirus-Host interactome: Identification of cyclophilins as target for pan-coronavirus inhibitors","volume":"7","author":"Pfefferle","year":"2011","journal-title":"PloS Pathog"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.034983-0","article-title":"Cyclosporin a inhibits the replication of diverse coronaviruses","volume":"92","author":"de Wilde","year":"2011","journal-title":"J Gen Virol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.052910-0","article-title":"Mers-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin a or interferon-\u03b1 treatment","volume":"94","author":"de Wilde","year":"2013","journal-title":"J Gen Virol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.1121","article-title":"Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis","volume":"155","author":"Dommasch","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2013.01.004","article-title":"Cyclosporine has a potential role in the treatment of sars","volume":"67","author":"Russell","year":"2013","journal-title":"J Infect"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17749","article-title":"Incidence and prognosis of covid-19 in patients with psoriasis on apremilast: A multicentre retrospective cohort study","volume":"36","author":"Lytvyn","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e13668","DOI":"10.1111\/dth.13668","article-title":"Apremilast as a potential treatment option for covid-19: No symptoms of infection in a psoriatic patient","volume":"33","author":"Olisova","year":"2020","journal-title":"Dermatol Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16625","article-title":"Covid-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: Safety and compatibility of apremilast with critical intensive care management","volume":"34","author":"Mugheddu","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1779217","article-title":"Status of a real-life cohort of patients with moderate-to-Severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the covid-19 era","volume":"20","author":"Galluzzo","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14781","article-title":"Letter to the Editor regarding the article \u201cOguz topal I, kara polat a, zindanc\u0131 \u0130, et\u00a0al. adherence to systemic therapy in patients with psoriasis during the covid-19 pandemic: A multicenter study. J cosmet dermatol. 2021;10.1111\/Jocd.14610.\u201d","volume":"21","author":"Potestio","year":"2022","journal-title":"J Cosmetic Dermatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.5336\/dermato.2021-86216","article-title":"The effects of covid-19 on psoriasis patients using biologic treatment: Two-center retrospective study","volume":"32","author":"Kus","year":"2022","journal-title":"Turkiye Klinikleri Dermatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaci.2020.10.007","article-title":"Factors associated with adverse covid-19 outcomes in patients with psoriasis-insights from a global registry-based study","volume":"147","author":"Mahil","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e13580","DOI":"10.1111\/dth.13580","article-title":"Covid-19 in an elderly patient treated with secukinumab","volume":"33","author":"Di Lernia","year":"2020","journal-title":"Dermatol Ther"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16571","article-title":"Sars-Cov-2 infection in a psoriatic patient treated with il-17 inhibitor","volume":"34","author":"Balestri","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14710","article-title":"Safety of secukinumab treatment in covid -19 affected psoriatic patients","volume":"34","author":"Mugheddu","year":"2021","journal-title":"Dermatol Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15008","article-title":"Complicated coronavirus disease 2019 (Covid-19) in a psoriatic patient treated with ixekizumab","volume":"59","author":"Facheris","year":"2020","journal-title":"Int J Dermatol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e13706","DOI":"10.1111\/dth.13706","article-title":"Psoriasis,Covid-19, and acute respiratory distress syndrome: Focusing on the risk of concomitant biological treatment","volume":"33","author":"Magnano","year":"2020","journal-title":"Dermatol Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15002","article-title":"Biologic agents in psoriasis: Our experience during coronavirus infection","volume":"59","author":"Strippoli","year":"2020","journal-title":"Int J Dermatol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e14011","DOI":"10.1111\/dth.14011","article-title":"Coronavirus disease 2019 (Covid-19) rash in a psoriatic patient treated with secukinumab: Is there a role for interleukin 17","volume":"33","author":"Carugno","year":"2020","journal-title":"Dermatol Ther"},{"key":"B65","doi-asserted-by":"publisher","first-page":"Si37","DOI":"10.1093\/rheumatology\/keab250","article-title":"Covid-19 in patients with autoimmune diseases: Characteristics and outcomes in a multinational network of cohorts across three countries","volume":"60","author":"Tan","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B66","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jaci.2021.01.006","article-title":"Associations between covid-19 and skin conditions identified through epidemiology and genomic studies","volume":"147","author":"Patrick","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with covid-19-Related death using opensafely","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20062","article-title":"Risk of covid-19 infection in adult patients with atopic eczema and psoriasis: A single-centre cross-sectional study","volume":"185","author":"Yiu","year":"2021","journal-title":"Br J Dermatol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.058","article-title":"National psoriasis foundation covid-19 task force guidance for management of psoriatic disease during the pandemic: Version 2-advances in psoriatic disease management, covid-19 vaccines, and covid-19 treatments","volume":"84","author":"IGelfand","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2010.02310.x","article-title":"Psoriasis is associated with clinically significant cardiovascular risk: A Danish nationwide cohort study","volume":"270","author":"Ahlehoff","year":"2011","journal-title":"J Intern Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2133.2009.09281.x","article-title":"More than skin deep: Atherosclerosis as a systemic manifestation of psoriasis","volume":"161","author":"Alexandroff","year":"2009","journal-title":"Br J Dermatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03096","article-title":"Il-17a in psoriasis and beyond: Cardiovascular and metabolic implications","volume":"10","author":"von Stebut","year":"2019","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.09.021","article-title":"Protection from psoriasis-related thrombosis after inhibition of il-23 or il-17a","volume":"138","author":"Li","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25685","article-title":"Coronavirus infections and immune responses","volume":"92","author":"Li","year":"2020","journal-title":"J Med Virol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"495","DOI":"10.5021\/ad.2019.31.5.495","article-title":"Is it possible to discontinue tumor necrosis factor antagonists after psoriasis remission","volume":"31","author":"Kim","year":"2019","journal-title":"Ann Dermatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13467","article-title":"Biologics for psoriasis in covid-19 era: What do we know","volume":"33","author":"IMegna","year":"2020","journal-title":"Dermatol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1046352\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T13:08:30Z","timestamp":1666876110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1046352\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":76,"alternative-id":["10.3389\/fimmu.2022.1046352"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1046352","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]},"article-number":"1046352"}}